EP2243493A1
(en)
|
2002-07-03 |
2010-10-27 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiative composition
|
SI2161336T1
(en)
|
2005-05-09 |
2013-11-29 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
EP1954311A4
(en)
*
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
Ctla-4 antibody dosage escalation regimens
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
KR20210060670A
(en)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
ES2895226T3
(en)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
US10022431B2
(en)
|
2010-02-10 |
2018-07-17 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
BR112012029066A2
(en)
|
2010-05-14 |
2020-09-01 |
The General Hospital Corporation |
compositions and processes for the identification of tumor-specific neoantigens.
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
EP2701699B1
(en)
|
2011-04-28 |
2019-10-16 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
ES2705950T3
(en)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
|
PL3485903T3
(en)
|
2011-09-23 |
2023-06-12 |
Mereo Biopharma 5, Inc. |
Vegf/dll4 binding agents and uses thereof
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP2825693B1
(en)
|
2012-03-15 |
2018-05-30 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
UY34887A
(en)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
JP6337255B2
(en)
|
2012-07-27 |
2018-06-06 |
ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
ES2660027T3
(en)
|
2012-10-01 |
2018-03-20 |
Adaptive Biotechnologies Corporation |
Evaluation of immunocompetence by the diversity of adaptive immunity receptors and clonal characterization
|
JP6371294B2
(en)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Methods and monitoring of treatment with DLL4 antagonists
|
AU2013355054B2
(en)
|
2012-12-07 |
2017-08-24 |
Chemocentryx, Inc. |
Diazole lactams
|
AR093984A1
(en)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
|
EP4356960A2
(en)
|
2013-03-15 |
2024-04-24 |
F. Hoffmann-La Roche AG |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
US20150071910A1
(en)
*
|
2013-03-15 |
2015-03-12 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
EP2981821B2
(en)
|
2013-04-02 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
CA2908380A1
(en)
|
2013-04-09 |
2014-10-16 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
DK2992017T3
(en)
|
2013-05-02 |
2021-01-25 |
Anaptysbio Inc |
ANTIBODIES AGAINST PROGRAMMED DEATH-1 (PD-1)
|
SG11201509742QA
(en)
|
2013-06-03 |
2015-12-30 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
GB2515038A
(en)
|
2013-06-11 |
2014-12-17 |
Cilag Gmbh Int |
Injection device
|
GB2515032A
(en)
|
2013-06-11 |
2014-12-17 |
Cilag Gmbh Int |
Guide for an injection device
|
GB2517896B
(en)
|
2013-06-11 |
2015-07-08 |
Cilag Gmbh Int |
Injection device
|
GB2515039B
(en)
|
2013-06-11 |
2015-05-27 |
Cilag Gmbh Int |
Injection Device
|
PT3027651T
(en)
|
2013-08-01 |
2019-05-31 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
JP6550053B2
(en)
*
|
2013-09-11 |
2019-07-24 |
メディミューン リミテッド |
Anti-B7-H1 antibody for treating a tumor
|
CN107011441B
(en)
|
2013-09-13 |
2020-12-01 |
百济神州(广州)生物科技有限公司 |
anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
|
RS64268B1
(en)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
US9663556B2
(en)
*
|
2013-10-04 |
2017-05-30 |
Pin Pharma, Inc. |
Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
|
EP3060581A4
(en)
*
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
RU2714142C2
(en)
*
|
2013-11-05 |
2020-02-12 |
Бавариан Нордик А/С |
Combination therapy for treating cancer with poxvirus expressing tumour antigen and antagonist and/or agonist of immune checkpoint inhibitor
|
AU2014346852A1
(en)
*
|
2013-11-05 |
2016-06-16 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
US20150164047A1
(en)
*
|
2013-11-07 |
2015-06-18 |
Urban Pet Haus, LLC |
Edible cat toy
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
EP3079772B1
(en)
*
|
2013-12-10 |
2020-02-05 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
|
EP3079699A4
(en)
*
|
2013-12-11 |
2017-07-19 |
Glaxosmithkline LLC |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
PT3081576T
(en)
|
2013-12-12 |
2019-10-15 |
Jiangsu Hengrui Medicine Co |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
EP3083686B2
(en)
*
|
2013-12-17 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
US20160312297A1
(en)
*
|
2013-12-17 |
2016-10-27 |
Merck Sharp & Dohme Corp. |
Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
|
EP3084001A4
(en)
*
|
2013-12-17 |
2017-07-12 |
Merck Sharp & Dohme Corp. |
Gene signature biomarkers of tumor response to pd-1 antagonists
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
GB201322725D0
(en)
*
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
CA3156357A1
(en)
|
2014-01-06 |
2015-07-09 |
The Trustees Of The University Of Pennsylvania |
Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
|
AU2015205755C1
(en)
|
2014-01-10 |
2020-08-13 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
TWI681969B
(en)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
Human antibodies to pd-1
|
TWI680138B
(en)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
Human antibodies to pd-l1
|
AU2015209133B2
(en)
|
2014-01-24 |
2019-10-03 |
AI Therapeutics, Inc. |
Apilimod compositions and methods for using same
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
WO2015116868A2
(en)
*
|
2014-01-29 |
2015-08-06 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
WO2015126903A1
(en)
*
|
2014-02-18 |
2015-08-27 |
Health Research, Inc. |
Combination therapy for hepatocellular carcinoma
|
MX2016010677A
(en)
*
|
2014-02-21 |
2017-04-10 |
Abbvie Stemcentrx Llc |
Anti-dll3 antibodies and drug conjugates for use in melanoma.
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015134605A1
(en)
|
2014-03-05 |
2015-09-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
US10188713B2
(en)
|
2014-03-19 |
2019-01-29 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
EP3119426A4
(en)
|
2014-03-19 |
2018-02-28 |
Mayo Foundation for Medical Education and Research |
Methods and materials for treating cancer
|
CN103897036B
(en)
*
|
2014-03-24 |
2016-02-24 |
郑州大学 |
A kind of PD-1 albumen extracellular fragment affinity peptide L8 and application thereof
|
US10583183B2
(en)
|
2014-04-11 |
2020-03-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Immune gene signatures in urothelial carcinoma (UC)
|
AU2015260962B2
(en)
*
|
2014-05-13 |
2020-06-11 |
Medimmune Limited |
Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
|
KR20170003692A
(en)
|
2014-05-15 |
2017-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
CA2947932C
(en)
|
2014-05-29 |
2021-03-30 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
WO2015181343A2
(en)
|
2014-05-30 |
2015-12-03 |
Ventana Medical Systems, Inc. |
Multiplex assay for improved scoring of tumor tissues stained for pd-l1
|
HUE047385T2
(en)
|
2014-06-06 |
2020-04-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2015192068A1
(en)
*
|
2014-06-12 |
2015-12-17 |
The Johns Hopkins University |
Combinatorial immunotherapy for pancreatic cancer treatment
|
TWI693232B
(en)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
|
EP3164194B1
(en)
*
|
2014-07-03 |
2021-11-24 |
Yale University |
Dickkopf2 (dkk2) inhibition suppresses tumor formation
|
KR102003754B1
(en)
*
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
|
WO2016006241A1
(en)
*
|
2014-07-09 |
2016-01-14 |
日本全薬工業株式会社 |
Anti-canine pd-1 antibody or anti-canine pd-l1 antibody
|
KR102462743B1
(en)
|
2014-07-09 |
2022-11-02 |
버디 바이오파마슈티칼즈, 인크. |
Anti-pd-l1 combinations for treating tumors
|
DK3309174T3
(en)
*
|
2014-07-11 |
2022-06-07 |
Ventana Med Syst Inc |
ANTI-PD-L1 antibodies and diagnostic uses thereof
|
LT3172232T
(en)
|
2014-07-17 |
2024-02-12 |
Novo Nordisk A/S |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
|
NZ728688A
(en)
|
2014-07-22 |
2023-06-30 |
Cb Therapeutics Inc |
Anti-pd-1 antibodies
|
JP6666343B2
(en)
*
|
2014-08-01 |
2020-03-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
Methods for treating tumors and combination therapeutics
|
CN105296433B
(en)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
A kind of CTLA4 antibody, its medical composition and its use
|
JP6909153B2
(en)
|
2014-08-05 |
2021-07-28 |
アポロミクス インコーポレイテッド |
Anti-PD-L1 antibody
|
JP6245622B2
(en)
*
|
2014-08-07 |
2017-12-13 |
学校法人兵庫医科大学 |
Cancer therapeutic agent using IL-18 and molecular target antibody in combination
|
TWI721954B
(en)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
High-purity quinoline derivative and production method thereof
|
CR20170086A
(en)
|
2014-09-09 |
2017-05-22 |
Janssen Biotech Inc |
COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES
|
CN107206071A
(en)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
The conjoint therapy of ALK inhibitor
|
EP3197918A1
(en)
|
2014-09-25 |
2017-08-02 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using an anti-fucosyl-gm1 antibody
|
ES2952717T3
(en)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Antibody molecules against PD-L1 and uses thereof
|
AU2015339306B2
(en)
|
2014-10-29 |
2021-07-22 |
Bristol-Myers Squibb Company |
Combination therapy for cancer
|
CN107530419B
(en)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
Combination therapy for treating disease
|
BR112017008799A2
(en)
|
2014-11-07 |
2017-12-19 |
Lam Therapeutics Inc |
apilimod compositions and methods of use in treating kidney cancer
|
CA2966660A1
(en)
|
2014-11-13 |
2016-05-19 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
TWI758928B
(en)
|
2014-11-21 |
2022-03-21 |
美商必治妥美雅史谷比公司 |
Antibodies against cd73 and uses thereof
|
DK3221346T3
(en)
|
2014-11-21 |
2020-10-12 |
Bristol Myers Squibb Co |
ANTIBODIES INCLUDING MODIFIED CONSTANT AREAS OF THE HEAVY CHAIN
|
JP6701217B2
(en)
|
2014-11-25 |
2020-05-27 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
18F-radiolabeling methods and compositions for biologics
|
CN114591420A
(en)
*
|
2014-11-25 |
2022-06-07 |
百时美施贵宝公司 |
Novel PD-L1 binding polypeptides for imaging
|
CA2969717A1
(en)
|
2014-12-04 |
2016-06-09 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
JP2017537927A
(en)
*
|
2014-12-04 |
2017-12-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
|
EP3233123A4
(en)
*
|
2014-12-16 |
2018-05-09 |
Bristol-Myers Squibb Company |
Use of immune checkpoint inhibitors in central nervous systems neoplasms
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
WO2016100975A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
JP6649953B2
(en)
*
|
2014-12-19 |
2020-02-19 |
スサヴィオン バイオサイエンシーズ インコーポレイテッド |
Immunotherapy treatments and compositions
|
US20170363614A1
(en)
*
|
2014-12-22 |
2017-12-21 |
Enumeral Biomedical Holdings, Inc. |
Methods For Screening Therapeutic Compounds
|
JP6180663B2
(en)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Antibodies against TIGIT
|
JP6743022B2
(en)
*
|
2014-12-24 |
2020-08-19 |
ネクシミューン インコーポレイテッド |
Nanoparticle compositions and methods for immunotherapy
|
EP3240908A2
(en)
*
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
GB201500374D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
US10034901B2
(en)
|
2015-01-22 |
2018-07-31 |
University Of Massachusetts |
Cancer immunotherapy
|
ES2791950T3
(en)
*
|
2015-02-03 |
2020-11-06 |
Ventana Med Syst Inc |
Histochemical assay to evaluate the expression of programmed death ligand 1 (PD-L1)
|
MA41460A
(en)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
TNFRSF LIAISON AGENTS AND THEIR USES
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
EP3256161A1
(en)
|
2015-02-09 |
2017-12-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
|
WO2016138182A1
(en)
*
|
2015-02-24 |
2016-09-01 |
Nodality, Inc. |
Methods and compositions for immunomodulation
|
RU2017128583A
(en)
|
2015-02-25 |
2019-03-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
METHOD FOR REDUCING THE BITTER OF A QUINOLINE DERIVATIVE
|
CN112263677A
(en)
*
|
2015-02-26 |
2021-01-26 |
默克专利股份公司 |
PD-1/PD-L1 inhibitors for the treatment of cancer
|
CA2978226A1
(en)
*
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
WO2016142532A1
(en)
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
US20180051084A1
(en)
*
|
2015-03-12 |
2018-02-22 |
Health Research, Inc. |
Combination of beta-adrenergic receptor antagonists and check point inhibitors for improved efficacy against cancer
|
MA42971A
(en)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
|
WO2016149387A1
(en)
*
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Androgen deprivation with immune checkpoint blockade delays the development of castration resistant prostate cancer
|
HUE048111T2
(en)
|
2015-03-23 |
2020-05-28 |
Bayer Pharma AG |
Anti-ceacam6 antibodies and uses thereof
|
WO2016162356A1
(en)
*
|
2015-04-07 |
2016-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-pd-l1 immunotoxin for use in therapy
|
US20180071413A1
(en)
*
|
2015-04-07 |
2018-03-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Non-invasive imaging of tumor pd-l1 expression
|
CA2987730C
(en)
|
2015-04-08 |
2020-02-18 |
Nantomics, Llc |
Cancer neoepitopes
|
HUE053903T2
(en)
|
2015-04-13 |
2021-07-28 |
Five Prime Therapeutics Inc |
Combination therapy for cancer
|
US20180312844A1
(en)
*
|
2015-04-13 |
2018-11-01 |
The Board of Regents of the UIniversity of Texas System |
Treatment for cancer metastasis
|
TN2017000440A1
(en)
*
|
2015-04-17 |
2019-04-12 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
CN108513593A
(en)
|
2015-04-23 |
2018-09-07 |
南托米克斯有限责任公司 |
The new epitope of cancer
|
EP3988571A1
(en)
|
2015-04-28 |
2022-04-27 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
US20160362489A1
(en)
*
|
2015-04-28 |
2016-12-15 |
Bristol-Myers Squibb Company |
Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
|
IL310108A
(en)
|
2015-05-06 |
2024-03-01 |
Snipr Tech Ltd |
Altering microbial populations & modifying microbiota
|
CN108136218B
(en)
|
2015-05-20 |
2022-12-13 |
詹森生物科技公司 |
anti-CD 38 antibodies for the treatment of light chain amyloidosis and other CD 38-positive hematologic malignancies
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
CN104931690A
(en)
*
|
2015-05-22 |
2015-09-23 |
华中科技大学同济医学院附属协和医院 |
PD-1 antibody detection kit and application thereof
|
WO2016191751A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
PT3303394T
(en)
|
2015-05-29 |
2020-07-01 |
Ludwig Inst For Cancer Res Ltd |
Anti-ctla-4 antibodies and methods of use thereof
|
WO2016196389A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
IL255372B
(en)
|
2015-05-29 |
2022-07-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
WO2016196228A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
EP3302557B1
(en)
*
|
2015-06-01 |
2024-01-31 |
MaineHealth |
Antagonist of collagen for enhancing the therapeutic activity of an immune checkpoint inhibitor in the treatment of melanoma
|
AU2016271475A1
(en)
|
2015-06-03 |
2017-12-21 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
US10995140B2
(en)
|
2015-06-05 |
2021-05-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
|
TWI773646B
(en)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
Lag-3-binding molecules and methods of use thereof
|
CN106243225B
(en)
*
|
2015-06-11 |
2021-01-19 |
智翔(上海)医药科技有限公司 |
Novel anti-PD-L1 antibodies
|
MX2017015811A
(en)
|
2015-06-12 |
2018-04-10 |
Squibb Bristol Myers Co |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways.
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
US10869924B2
(en)
|
2015-06-16 |
2020-12-22 |
Merck Patent Gmbh |
PD-L1 antagonist combination treatments
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
JP6816038B2
(en)
|
2015-06-22 |
2021-01-20 |
ヤンセン バイオテツク,インコーポレーテツド |
Combination therapy for hematological malignancies with anti-CD38 antibody and survivin inhibitor
|
EP3319635B1
(en)
*
|
2015-06-24 |
2021-04-21 |
Immodulon Therapeutics Limited |
A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
|
US20170044265A1
(en)
*
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
BR112017027990A2
(en)
*
|
2015-06-24 |
2018-08-28 |
Janssen Biotech, Inc. |
immune modulation and treatment of solid tumors with antibodies that specifically bind to cd38
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
EP3313382A4
(en)
*
|
2015-06-29 |
2019-03-06 |
Abraxis BioScience, LLC |
Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
|
JP6786529B2
(en)
|
2015-06-29 |
2020-11-18 |
バイオメッド バレー ディスカバリーズ,インコーポレイティド |
Combination of LPT-723 and Immune Checkpoint Inhibitors and Methods of Treatment
|
ES2897991T3
(en)
|
2015-06-29 |
2022-03-03 |
Abraxis Bioscience Llc |
Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
|
WO2017004016A1
(en)
|
2015-06-29 |
2017-01-05 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
CN108289858A
(en)
*
|
2015-06-30 |
2018-07-17 |
宾夕法尼亚州立大学托管会 |
The not special local Injectable composition of auspicious quinoline for treating neoplastic cutaneous diseases
|
AU2016294440B2
(en)
*
|
2015-07-13 |
2022-10-13 |
Cytomx Therapeutics, Inc |
Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
|
WO2017011439A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
|
SI3322731T1
(en)
|
2015-07-14 |
2021-03-31 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
|
MA42459A
(en)
|
2015-07-16 |
2018-05-23 |
Bioxcel Therapeutics Inc |
NEW APPROACH TO CANCER TREATMENT BY IMMUNOMODULATION
|
HUE056201T2
(en)
|
2015-07-30 |
2022-02-28 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
EP3328896A4
(en)
|
2015-07-31 |
2019-08-07 |
University of Florida Research Foundation, Inc. |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
CN106397592A
(en)
*
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
|
US11008391B2
(en)
|
2015-08-11 |
2021-05-18 |
WuXi Biologics Ireland Limited |
Anti-PD-1 antibodies
|
KR20220131277A
(en)
|
2015-09-01 |
2022-09-27 |
아게누스 인코포레이티드 |
Anti-pd-1 antibodies and methods of use thereof
|
WO2017040960A1
(en)
*
|
2015-09-04 |
2017-03-09 |
The Brigham And Women's Hospital, Inc. |
Programmed cell death 1 (pd-1 ) inhibitor therapy for patients with pd-1 -expressing cancers
|
EP3349731B1
(en)
|
2015-09-16 |
2023-11-01 |
Board of Regents, The University of Texas System |
Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
|
ES2968074T3
(en)
|
2015-09-23 |
2024-05-07 |
Mereo Biopharma 5 Inc |
Bi-specific anti-VEGF/DLL4 antibody for use in the treatment of platinum-resistant ovarian cancer
|
US20210284734A1
(en)
*
|
2015-10-02 |
2021-09-16 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
US10273281B2
(en)
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
BR112018008891A8
(en)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
antibodies that specifically bind to pd-1 and tim-3 and their uses
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
MA53356B1
(en)
|
2015-11-03 |
2022-05-31 |
Janssen Biotech Inc |
Subcutaneous anti-cd38 antibody formulations and uses thereof
|
WO2017076360A1
(en)
*
|
2015-11-04 |
2017-05-11 |
Taipei Veterans General Hospital |
Title of the invention combination therapy for malignant diseases
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
JP6983371B2
(en)
|
2015-11-17 |
2021-12-17 |
スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド |
Anti-PD-L1 antibody, its antigen-binding fragment and its medical use
|
WO2017087870A1
(en)
|
2015-11-18 |
2017-05-26 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA3005730A1
(en)
*
|
2015-11-20 |
2017-05-26 |
Senhwa Biosciences, Inc. |
Combination therapy of tetracyclic quinolone analogs for treating cancer
|
WO2017085307A1
(en)
|
2015-11-22 |
2017-05-26 |
Ventana Medical Systems, Inc. |
Methods of identifying immune cells in pd-l1 positive tumor tissue
|
WO2017091580A1
(en)
*
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Predicting response to cancer treatment with fgfr2 inhibitors
|
EP3384269A4
(en)
*
|
2015-12-02 |
2019-05-01 |
Clearlight Diagnostics LLC |
Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
|
CN107849084B
(en)
|
2015-12-03 |
2021-09-14 |
葛兰素史密斯克莱知识产权发展有限公司 |
Cyclic purine dinucleotides as STING modulators
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
TWI758267B
(en)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
KR102378298B1
(en)
*
|
2015-12-18 |
2022-03-23 |
인스티튜트 구스타브 루시 |
Methods for evaluating response to PD-1/PDL-1 targeting drug
|
LT3394093T
(en)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
CN115252792A
(en)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
anti-EGFR combinations for the treatment of tumors
|
CN115554406A
(en)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
anti-CD 20 combinations for the treatment of tumors
|
WO2017123911A1
(en)
*
|
2016-01-15 |
2017-07-20 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
CN105717298A
(en)
*
|
2016-01-29 |
2016-06-29 |
浙江数问生物技术有限公司 |
PD-L1 immunohistochemical kit
|
US11710539B2
(en)
|
2016-02-01 |
2023-07-25 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
|
ES2877568T3
(en)
|
2016-02-05 |
2021-11-17 |
Orionis Biosciences Nv |
Clec9A binding agents
|
WO2017139755A1
(en)
*
|
2016-02-12 |
2017-08-17 |
Rekoske Brian T |
Cancer therapy
|
US10906977B2
(en)
*
|
2016-02-18 |
2021-02-02 |
Maine Medical Center Research Institute |
Enhancing the therapeutic activity of immune checkpoint inhibitor
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
ES2801873T3
(en)
|
2016-03-04 |
2021-01-14 |
Sichuan Kelun Biotech Biopharmaceutical Co Ltd |
PDL-1 antibody, its pharmaceutical composition and its uses
|
WO2017156152A1
(en)
*
|
2016-03-08 |
2017-09-14 |
Bioxcel Corporation |
Immunomodulation therapies for cancer
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
CA3007135A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
EP4029517A1
(en)
*
|
2016-03-31 |
2022-07-20 |
Jiangsu Yahong Meditech Co., Ltd. |
Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
JP2019510832A
(en)
|
2016-04-07 |
2019-04-18 |
ケモセントリクス,インコーポレーテッド |
Reduction of tumor burden by administering a CCR1 antagonist in combination with a PD-1 inhibitor or PD-L1 inhibitor
|
WO2017176565A1
(en)
|
2016-04-07 |
2017-10-12 |
Eli Lilly And Company |
Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
|
KR20180132783A
(en)
|
2016-04-07 |
2018-12-12 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Heterocyclic amides useful as protein modulators
|
KR102527784B1
(en)
|
2016-04-07 |
2023-04-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Heterocyclic amides useful as protein modulators
|
CN109311989A
(en)
*
|
2016-04-14 |
2019-02-05 |
创新微技术公司 |
The application method of PD-L1 expression in the treatment of cancer therapy determines
|
WO2017181034A1
(en)
|
2016-04-14 |
2017-10-19 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
WO2017189526A1
(en)
*
|
2016-04-25 |
2017-11-02 |
Musc Foundation For Research Development |
Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
|
CN109328188A
(en)
|
2016-05-05 |
2019-02-12 |
葛兰素史密斯克莱知识产权(第2 号)有限公司 |
2 inhibitor of ZESTE enhancer homologue
|
CN109689087B
(en)
|
2016-05-13 |
2023-04-04 |
奥里尼斯生物科学私人有限公司 |
Targeted mutant interferon-beta and uses thereof
|
CN109563141A
(en)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
To the therapeutic targeting of cellular structures
|
TWI755395B
(en)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
Combination of anti-pd-1 antibodies and radiation to treat cancer
|
CN109476718B
(en)
|
2016-05-18 |
2023-07-04 |
莫得纳特斯公司 |
Combination of MRNA encoding immunomodulatory polypeptides and uses thereof
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
EP4186518A1
(en)
|
2016-05-18 |
2023-05-31 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
ES2912131T3
(en)
|
2016-05-20 |
2022-05-24 |
Biohaven Therapeutics Ltd |
Use of glutamate modulating agents with immunotherapies to treat cancer
|
WO2017205801A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Takeda Pharmaceutical Company Limited |
Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
|
US11786533B2
(en)
|
2016-06-01 |
2023-10-17 |
Epizyme, Inc. |
Use of EZH2 inhibitors for treating cancer
|
JP7016323B2
(en)
|
2016-06-01 |
2022-02-21 |
ブリストル-マイヤーズ スクイブ カンパニー |
PET contrast using PD-L1 binding polypeptide
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
KR20230119265A
(en)
|
2016-06-02 |
2023-08-16 |
브리스톨-마이어스 스큅 컴퍼니 |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
KR20230038318A
(en)
|
2016-06-02 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
|
CN109475634A
(en)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
For treating the anti-PD-1 antibody of the method for relapsed small cell lung cancer
|
KR20230118713A
(en)
*
|
2016-06-03 |
2023-08-11 |
브리스톨-마이어스 스큅 컴퍼니 |
Anti-pd-1 antibody for use in a method of treating a tumor
|
ES2897964T3
(en)
|
2016-06-03 |
2022-03-03 |
Bristol Myers Squibb Co |
Use of anti-PD-1 antibody in the treatment of patients with colorectal cancer
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
WO2017214182A1
(en)
*
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
WO2017212423A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemcical compounds
|
EP3468960B1
(en)
|
2016-06-08 |
2022-03-23 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
CN107488229B
(en)
*
|
2016-06-13 |
2020-11-17 |
天境生物科技(上海)有限公司 |
PD-L1 antibodies and uses thereof
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
RU2756236C2
(en)
|
2016-06-20 |
2021-09-28 |
Кимаб Лимитед |
Pd-l1 specific antibodies
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
AU2017290803A1
(en)
|
2016-06-30 |
2019-01-24 |
Nant Holdings Ip, Llc |
Nant cancer vaccine
|
CN109475536B
(en)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
Combination of a PD-l antagonist and a RAF inhibitor for the treatment of cancer
|
PE20190418A1
(en)
|
2016-07-14 |
2019-03-19 |
Bristol Myers Squibb Co |
ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES
|
US20190241573A1
(en)
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
US11649289B2
(en)
*
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
BR112019002529A2
(en)
|
2016-08-09 |
2019-05-28 |
Kymab Ltd |
isolated antibody, composition, method for modulating t-cell balance, method for treating a therapy-treatable disease or condition, method for treating cancer, igg1 antibody combination, anti-ics antibody, transgenic non-human mammal, and method for producing a antibody
|
KR101966496B1
(en)
|
2016-08-18 |
2019-04-08 |
울산대학교 산학협력단 |
USB security locking apparatus using mechanical locking type
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
ES2937291T3
(en)
*
|
2016-09-01 |
2023-03-27 |
Mayo Found Medical Education & Res |
Compositions of Agents That Bind to the PD-L1 Transporter and Methods of Using Them to Treat Cancers
|
US11726089B2
(en)
|
2016-09-06 |
2023-08-15 |
Incelldx, Inc. |
Methods of assaying neoplastic and neoplasia-related cells and uses thereof
|
WO2018048936A1
(en)
*
|
2016-09-06 |
2018-03-15 |
Incelldx, Inc. |
Methods of detecting per cell pd-l1 expression and uses thereof
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
CA3035976A1
(en)
|
2016-09-09 |
2018-03-15 |
Tg Therapeutics, Inc. |
Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
|
KR102557336B1
(en)
*
|
2016-09-13 |
2023-07-18 |
노쓰 캐롤라이나 스테이트 유니버시티 |
Platelet Compositions and Methods of Delivery of Therapeutic Agents
|
CA3037230A1
(en)
*
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
AU2017339856A1
(en)
|
2016-10-06 |
2019-05-23 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
BR112019007450A2
(en)
|
2016-10-14 |
2020-07-07 |
Precision Biosciences, Inc. |
modified meganucleases specific for recognition sequences in the hepatitis b virus genome
|
US10597454B2
(en)
|
2016-10-15 |
2020-03-24 |
Innovent Biologics (Suzhou) Co., Ltd |
PD-1 antibodies
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
WO2018081621A1
(en)
|
2016-10-28 |
2018-05-03 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
EP3532638A4
(en)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
US11155624B2
(en)
|
2016-11-01 |
2021-10-26 |
Anaptysbio, Inc. |
Antibodies directed against programmed death-1 (PD-1)
|
CN110167964B
(en)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
Combination of bispecific antibodies and immunopharmaceuticals against BCMA and CD3 for the treatment of multiple myeloma
|
HUE057559T2
(en)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
Antibodies to pd-1 and uses thereof
|
US11117968B2
(en)
|
2016-11-03 |
2021-09-14 |
Bristol-Myers Squibb Company |
Activatable anti-CTLA-4 antibodies and uses thereof
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
AU2017355512A1
(en)
|
2016-11-04 |
2019-05-23 |
Aximmune, Inc. |
Beta-alethine, immune modulators, and uses thereof
|
US11471515B2
(en)
|
2016-11-09 |
2022-10-18 |
The Brigham And Women's Hospital, Inc. |
Restoration of tumor suppression using MRNA-based delivery system
|
US11220543B2
(en)
*
|
2016-11-14 |
2022-01-11 |
Dinona |
Antibody binding specifically to CD66c and use thereof
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
WO2018101448A1
(en)
|
2016-11-30 |
2018-06-07 |
Kyowa Hakko Kirin Co., Ltd. |
Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
|
JP2020500878A
(en)
*
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
CA3045243A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
BR112019012154A2
(en)
|
2016-12-14 |
2019-11-12 |
Janssen Biotech Inc |
cd8a-binding fibronectin type iii domains
|
CN106519034B
(en)
*
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
anti-PD-1 antibodies and uses thereof
|
WO2018129301A1
(en)
|
2017-01-05 |
2018-07-12 |
Biodesix, Inc. |
Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
|
KR102606252B1
(en)
|
2017-01-09 |
2023-11-23 |
테사로, 인코포레이티드 |
How to Treat Cancer with Anti-PD-1 Antibodies
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
US11384154B2
(en)
|
2017-02-06 |
2022-07-12 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
CN110662764B
(en)
|
2017-02-16 |
2023-08-22 |
湘潭腾华生物科技有限公司 |
Anti-programmed death ligand 1 (PD-L1) antibodies and therapeutic uses thereof
|
TWI674261B
(en)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 modulators
|
CA3052767A1
(en)
|
2017-02-27 |
2018-08-30 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
EP3589652A4
(en)
|
2017-03-04 |
2021-05-05 |
Xiangtan Tenghua Bioscience |
Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
|
AU2018231618A1
(en)
|
2017-03-09 |
2019-10-03 |
Genmab A/S |
Antibodies against PD-L1
|
CN110709420A
(en)
|
2017-03-31 |
2020-01-17 |
戊瑞治疗有限公司 |
Combination cancer therapy with anti-GITR antibodies
|
BR112019019795A2
(en)
|
2017-03-31 |
2020-04-22 |
Bristol-Myers Squibb Company |
methods to treat tumor
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
CN108794467A
(en)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2- amino-quinoline derivatives
|
EP3619230A4
(en)
*
|
2017-05-01 |
2021-04-21 |
The Children's Medical Center Corporation |
Methods and compositions relating to anti-pd1 antibody reagents
|
AU2018261434B2
(en)
*
|
2017-05-02 |
2024-03-07 |
Dana-Farber Cancer Institute, Inc. |
IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
|
JP7090347B2
(en)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス,インク. |
Mesothelin-binding protein
|
CA3062177A1
(en)
|
2017-05-16 |
2018-11-22 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
JP7274426B2
(en)
|
2017-05-16 |
2023-05-16 |
ブリストル-マイヤーズ スクイブ カンパニー |
Treatment of cancer with anti-GITR agonist antibodies
|
JP2020520923A
(en)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル, インコーポレイテッド |
Methods for treating cancer
|
JP7285220B2
(en)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides
|
MX2019013132A
(en)
|
2017-05-25 |
2020-01-27 |
Bristol Myers Squibb Co |
Antibodies comprising modified heavy constant regions.
|
WO2018222722A2
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
HRP20231457T1
(en)
|
2017-05-30 |
2024-05-10 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
EP4245375A3
(en)
|
2017-05-30 |
2023-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
WO2018223040A1
(en)
|
2017-06-01 |
2018-12-06 |
Bristol-Myers Squibb Company |
Methods of treating a tumor using an anti-pd-1 antibody
|
JP2020522486A
(en)
*
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
Activatable anti-PDL1 antibody and method of using the same
|
CN110944628A
(en)
*
|
2017-06-02 |
2020-03-31 |
Epizyme股份有限公司 |
Treatment of cancer with EZH2 inhibitors
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
EP3634483A1
(en)
|
2017-06-09 |
2020-04-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
EP3641771A4
(en)
|
2017-06-23 |
2020-12-16 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
EP3645569A4
(en)
*
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
KR102454460B1
(en)
|
2017-06-27 |
2022-10-17 |
주식회사 뉴라클사이언스 |
Use of anti-FAM19A5 antibody for the treatment of cancer
|
EP3649108A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
WO2019008506A1
(en)
|
2017-07-03 |
2019-01-10 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
JP2020526844A
(en)
*
|
2017-07-13 |
2020-08-31 |
アンスティテュ・ギュスターヴ・ルシー |
Radiomics-based imaging tool for monitoring tumor lymphocyte infiltration and outcome in cancer patients treated with anti-PD-1 / PD-L1
|
AU2018301681B2
(en)
|
2017-07-14 |
2022-07-14 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
Indazole derivatives useful as perk inhibitors
|
WO2019023624A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
Predictive peripheral blood biomarker for checkpoint inhibitors
|
AU2018309339A1
(en)
|
2017-08-04 |
2020-02-20 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer
|
TWI785098B
(en)
|
2017-08-18 |
2022-12-01 |
開曼群島商科賽睿生命科學公司 |
Polymorphic form of tg02
|
KR20200044899A
(en)
*
|
2017-08-28 |
2020-04-29 |
브리스톨-마이어스 스큅 컴퍼니 |
TIM-3 antagonist for the treatment and diagnosis of cancer
|
WO2019051164A1
(en)
|
2017-09-07 |
2019-03-14 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
UY37866A
(en)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
NEW SUBSTITUTED BENZOIMIDAZOL COMPOUNDS THAT REDUCE MYC PROTEIN (C-MYC) IN THE CELLS AND INHIBIT THE HISTONE ACETYLTRANSPHERASE OF P300 / CBP.
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
CA3073531A1
(en)
|
2017-09-13 |
2019-03-21 |
Five Prime Therapeutics, Inc. |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
SG11202002119QA
(en)
|
2017-09-25 |
2020-04-29 |
Chemocentryx Inc |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
EP3692033A1
(en)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting) useful in treating hiv
|
BR112020006780A2
(en)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
modulators of the interferon gene stimulator (sting)
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
AU2018346955A1
(en)
|
2017-10-13 |
2020-04-30 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
CN111247169A
(en)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
Method for treating tumors
|
CA3079242A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
CN111542544A
(en)
|
2017-11-01 |
2020-08-14 |
百时美施贵宝公司 |
Immunostimulatory antibodies for the treatment of cancer
|
DE102017125780B3
(en)
*
|
2017-11-05 |
2018-12-13 |
Dimo Dietrich |
Method for determining the response of a malignant disease to immunotherapy
|
WO2019090330A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
CN111373261A
(en)
*
|
2017-11-20 |
2020-07-03 |
尤利乌斯·马克西米利安维尔茨堡大学 |
CD19CART cells can eliminate myeloma cells expressing very low levels of CD19
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
CN107973854B
(en)
*
|
2017-12-11 |
2021-05-04 |
苏州银河生物医药有限公司 |
PDL1 monoclonal antibody and application thereof
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
WO2019123340A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CN109970857B
(en)
*
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
anti-PD-L1 antibodies and uses thereof
|
JP7284759B2
(en)
|
2017-12-27 |
2023-05-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
ANTI-CD40 ANTIBODY AND USES THEREOF
|
AU2018394939B2
(en)
|
2017-12-29 |
2022-02-24 |
Ap Biosciences, Inc. |
Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
|
EP3735272A4
(en)
*
|
2018-01-05 |
2021-09-22 |
Biograph 55, Inc. |
Compositions and methods for cancer immunotherapy
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
WO2019136368A2
(en)
|
2018-01-08 |
2019-07-11 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
US11359021B2
(en)
|
2018-01-10 |
2022-06-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
US20210177781A9
(en)
|
2018-01-12 |
2021-06-17 |
KDAc Therapeutics, Inc. |
Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
|
MX2020006171A
(en)
|
2018-01-12 |
2020-09-03 |
Bristol Myers Squibb Co |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer.
|
EP3737700A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
EP3743061A1
(en)
|
2018-01-22 |
2020-12-02 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
CN111629731A
(en)
|
2018-01-22 |
2020-09-04 |
百时美施贵宝公司 |
Compositions and methods for treating cancer
|
US11814623B2
(en)
|
2018-01-30 |
2023-11-14 |
University Of Massachusetts |
Methods of treating a wound using epigenetic regulation
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
AU2019215440A1
(en)
|
2018-02-05 |
2020-08-27 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
EP3749330A4
(en)
|
2018-02-06 |
2021-11-17 |
The General Hospital Corporation |
Repeat rna as biomarkers of tumor immune response
|
US20200405806A1
(en)
|
2018-02-08 |
2020-12-31 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
WO2019168688A2
(en)
|
2018-02-15 |
2019-09-06 |
Senhwa Biosciences, Inc. |
Quinolone analogs and their salts, compositions, and method for their use
|
US20210002649A1
(en)
*
|
2018-03-01 |
2021-01-07 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for treating cancer
|
KR102043468B1
(en)
|
2018-03-14 |
2019-11-11 |
경북대학교 산학협력단 |
An Information Providing Method for Predicting Recurrence of Epstein-Barr virus-associated Gastric Cancer
|
WO2019175328A1
(en)
|
2018-03-14 |
2019-09-19 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Bh4pathwayactivationandusethereoffortreatingcancer
|
KR20230020023A
(en)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Antibodies that bind cd39 and uses thereof
|
JP2021518133A
(en)
|
2018-03-21 |
2021-08-02 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
Antibodies that bind to VISTA at acidic pH
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
CN111886256A
(en)
|
2018-03-23 |
2020-11-03 |
百时美施贵宝公司 |
anti-MICA and/or MICB antibodies and uses thereof
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
KR20200139724A
(en)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
How to treat a tumor
|
TW202003569A
(en)
|
2018-03-30 |
2020-01-16 |
荷蘭商美勒斯公司 |
Multivalent antibody
|
CN112292399A
(en)
|
2018-04-04 |
2021-01-29 |
百时美施贵宝公司 |
anti-CD27 antibodies and uses thereof
|
WO2019195658A1
(en)
|
2018-04-05 |
2019-10-10 |
Dana-Farber Cancer Institute, Inc. |
Sting levels as a biomarker for cancer immunotherapy
|
TWI818007B
(en)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-cyclic dinucleotides
|
CA3093888A1
(en)
|
2018-04-06 |
2019-10-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
IL303335A
(en)
|
2018-04-09 |
2023-07-01 |
Eisai R&D Man Co Ltd |
Pladienolide compounds and their use
|
JP7334181B2
(en)
|
2018-04-12 |
2023-08-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Pladienolide derivatives as spliceosome-targeting agents for cancer therapy
|
MX2020010604A
(en)
|
2018-04-12 |
2020-10-20 |
Bristol Myers Squibb Co |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody.
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
EP3781689A1
(en)
|
2018-04-19 |
2021-02-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
CN112074516A
(en)
|
2018-04-25 |
2020-12-11 |
先天肿瘤免疫公司 |
NLRP3 modulators
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
IL278400B2
(en)
|
2018-05-07 |
2024-03-01 |
Genmab As |
Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
EP3801523A2
(en)
|
2018-06-01 |
2021-04-14 |
Eisai R&D Management Co., Ltd. |
Methods of using splicing modulators
|
TW202015739A
(en)
|
2018-06-01 |
2020-05-01 |
日商衛材R&D企管股份有限公司 |
Splicing modulator antibody-drug conjugates and methods of use
|
WO2019234576A1
(en)
|
2018-06-03 |
2019-12-12 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
US20220017617A1
(en)
*
|
2018-07-09 |
2022-01-20 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
Efficiently expressed egfr and pd-l1 bispecific binding proteins
|
CA3105942A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
MX2021000009A
(en)
|
2018-07-09 |
2021-03-09 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4.
|
US20220073617A1
(en)
|
2018-07-11 |
2022-03-10 |
Five Prime Therapeutics, Inc. |
Antibodies Binding to Vista at Acidic pH
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
JP7072715B2
(en)
|
2018-07-20 |
2022-05-20 |
サーフィス オンコロジー インコーポレイテッド |
Anti-CD112R Compositions and Methods
|
CA3107660A1
(en)
|
2018-07-26 |
2020-01-30 |
Bristol-Myers Squibb Company |
Lag-3 combination therapy for the treatment of cancer
|
US20210292851A1
(en)
*
|
2018-07-27 |
2021-09-23 |
Roche Sequencing Solutions, Inc. |
Method of monitoring effectiveness of immunotherapy of cancer patients
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
CN112996567A
(en)
|
2018-08-16 |
2021-06-18 |
先天肿瘤免疫公司 |
Imidazo [4,5-C ] quinoline-derived NLRP 3-modulators
|
MX2021001581A
(en)
|
2018-08-16 |
2021-04-19 |
Innate Tumor Immunity Inc |
SUBSTITUED 4-AMINO-<i>1H</i>-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION.
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
WO2020061060A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
JP7425049B2
(en)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
DLL3 binding protein and method of use
|
CN112839962A
(en)
|
2018-10-09 |
2021-05-25 |
百时美施贵宝公司 |
Anti-merk antibodies for the treatment of cancer
|
CN113164780A
(en)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
anti-LAP antibody variants and uses thereof
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
KR20210080437A
(en)
|
2018-10-19 |
2021-06-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Combination Therapy for Melanoma
|
EP3870219A1
(en)
|
2018-10-22 |
2021-09-01 |
GlaxoSmithKline Intellectual Property Development Ltd |
Dosing
|
WO2020086724A1
(en)
|
2018-10-23 |
2020-04-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
BR112021008057A2
(en)
|
2018-10-30 |
2021-08-10 |
Genmab A/S |
method for treating cervical cancer, and kit
|
WO2020089432A1
(en)
*
|
2018-11-02 |
2020-05-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New prognostic method of pancreatic cancer
|
BR112021008774A2
(en)
|
2018-11-06 |
2021-11-30 |
BioNTech SE |
Pharmaceutical formulation, binding agent, methods for treating a disease, for producing a pharmaceutical formulation, for inducing cell death or inhibiting the growth and/or proliferation of a tumor cell, and, use of a pharmaceutical formulation
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
BR112021007448A2
(en)
|
2018-11-14 |
2021-10-26 |
Bayer Aktiengesellschaft |
PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER
|
US20220008515A1
(en)
|
2018-11-16 |
2022-01-13 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
KR20210092769A
(en)
|
2018-11-16 |
2021-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
Anti-NKG2A antibodies and uses thereof
|
AU2019379179A1
(en)
|
2018-11-16 |
2021-06-10 |
Arqule, Inc. |
Pharmaceutical combination for treatment of cancer
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
CN113613724A
(en)
|
2018-11-30 |
2021-11-05 |
葛兰素史克知识产权开发有限公司 |
Compounds useful in HIV therapy
|
KR20210098504A
(en)
|
2018-12-04 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Analytical Methods Using In-Sample Calibration Curves by Monitoring Multiple Isotope Responses
|
KR20210102274A
(en)
|
2018-12-13 |
2021-08-19 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Herboxidiene Antibody-Drug Conjugates and Methods of Use
|
CA3124773A1
(en)
|
2018-12-28 |
2020-07-02 |
Transgene |
M2-defective poxvirus
|
JP2022517112A
(en)
|
2019-01-14 |
2022-03-04 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
NLRP3 modulator
|
WO2020150115A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
ES2930151T3
(en)
|
2019-01-14 |
2022-12-07 |
Innate Tumor Immunity Inc |
NLRP3 heterocyclic modulators, for use in cancer treatment
|
WO2020150113A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
CA3128104A1
(en)
|
2019-02-03 |
2020-08-06 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
|
WO2020163589A1
(en)
*
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
AU2020248002A1
(en)
|
2019-03-26 |
2021-10-21 |
The Regents Of The University Of Michigan |
Small molecule degraders of STAT3
|
JP2022526960A
(en)
|
2019-03-28 |
2022-05-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
How to treat a tumor
|
WO2020198672A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
EP3947403A1
(en)
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
WO2020208612A1
(en)
|
2019-04-12 |
2020-10-15 |
Vascular Biogenics Ltd. |
Methods of anti-tumor therapy
|
US20220227761A1
(en)
|
2019-05-16 |
2022-07-21 |
Stingthera, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
JP2022533194A
(en)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
Benzo [B] [1,8] Diazanaphthalene Acetic Acid Derivatives and Usage
|
EP3972982A1
(en)
|
2019-05-20 |
2022-03-30 |
Massachusetts Institute of Technology |
Boronic ester prodrugs and uses thereof
|
WO2020236850A1
(en)
*
|
2019-05-20 |
2020-11-26 |
Immunovalent Therapeutics Inc. |
Solid phase devices and methods of use for purifying and quantifying tissue-specific leukocytes
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
EP3976832A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
US20220306683A1
(en)
*
|
2019-06-07 |
2022-09-29 |
The Trustees Of Princeton University |
Proximity-based labeling systems and applications thereof
|
JP2022536728A
(en)
|
2019-06-12 |
2022-08-18 |
ヴァンダービルト ユニバーシティー |
Dibenzylamines as amino acid transport inhibitors
|
EP3983084A1
(en)
|
2019-06-12 |
2022-04-20 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
CN110684844B
(en)
*
|
2019-06-27 |
2023-01-24 |
中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) |
Application of p.P476S mutation of RBPJL gene as PD-1 antibody medication guide marker
|
GB201910138D0
(en)
|
2019-07-15 |
2019-08-28 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
EP3999510A1
(en)
|
2019-07-16 |
2022-05-25 |
The Regents Of The University Of Michigan |
Imidazopyrimidines as eed inhibitors and the use thereof
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
US11851490B2
(en)
|
2019-08-15 |
2023-12-26 |
Northwestern University |
Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
CN114641337A
(en)
|
2019-08-27 |
2022-06-17 |
密歇根大学董事会 |
CEREBLON E3 ligase inhibitors
|
CN113795510A
(en)
*
|
2019-08-29 |
2021-12-14 |
荣昌生物制药(烟台)股份有限公司 |
anti-PD-L1 antibody and application thereof
|
TW202124444A
(en)
|
2019-09-16 |
2021-07-01 |
美商表面腫瘤學公司 |
Anti-cd39 antibody compositions and methods
|
KR20220113353A
(en)
|
2019-09-18 |
2022-08-12 |
람캅 바이오 알파 에이지 |
Bispecific antibodies to CEACAM5 and CD3
|
AU2020348849A1
(en)
|
2019-09-19 |
2022-04-07 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
JP2022548292A
(en)
|
2019-09-19 |
2022-11-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies that bind VISTA at acidic pH
|
CN114450028A
(en)
|
2019-09-22 |
2022-05-06 |
百时美施贵宝公司 |
Quantitative spatial profiling for LAG-3antagonist therapy
|
US11667709B2
(en)
|
2019-09-24 |
2023-06-06 |
Industrial Technology Research Institute |
Anti-TIGIT antibodies and methods of use
|
TW202128752A
(en)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
Anti-il-27 antibodies and uses thereof
|
AU2020353079A1
(en)
|
2019-09-25 |
2022-04-14 |
Bristol-Myers Squibb Company |
Composite biomarker for cancer therapy
|
CA3151928A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Nikolai Kley |
Pd-l1 targeted chimeric proteins and uses thereof
|
CN114729049A
(en)
|
2019-09-27 |
2022-07-08 |
葛兰素史密斯克莱知识产权发展有限公司 |
Antigen binding proteins
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
EP4045061A4
(en)
|
2019-10-14 |
2024-04-17 |
Aro Biotherapeutics Company |
Cd71 binding fibronectin type iii domains
|
WO2021074683A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
Bispecific anti-pd-l1 and anti-fcrn polypeptides
|
CA3155202A1
(en)
|
2019-10-23 |
2021-04-29 |
Arthur M. Krieg |
Synthetic rig-i-like receptor agonists
|
KR102325962B1
(en)
*
|
2019-10-28 |
2021-11-12 |
경북대학교 산학협력단 |
Use for inhibiting exosome secretion or PD-L1 expression by calcium channel blockers
|
BR112022008557A2
(en)
|
2019-11-04 |
2022-08-09 |
Seagen Inc |
ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF HIV INFECTION
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
TW202132343A
(en)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
CN115942973A
(en)
|
2019-11-08 |
2023-04-07 |
百时美施贵宝公司 |
LAG-3 antagonist therapy for melanoma
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
BR112022009631A2
(en)
|
2019-12-19 |
2022-08-09 |
Bristol Myers Squibb Co |
COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS
|
EP4087842A1
(en)
|
2020-01-10 |
2022-11-16 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
KR20220133196A
(en)
|
2020-01-29 |
2022-10-04 |
메뤼스 엔.페. |
Means and methods for modulating the effects of immune cell involvement
|
CA3168923A1
(en)
|
2020-01-30 |
2021-08-05 |
ONA Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
JP2023515633A
(en)
|
2020-02-28 |
2023-04-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
Radiolabeled fibronectin-based scaffolds and antibodies and their theranostic uses
|
WO2021178807A1
(en)
|
2020-03-06 |
2021-09-10 |
Celgene Quanticel Research, Inc. |
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
|
BR112022016720A2
(en)
|
2020-03-06 |
2022-11-16 |
Ona Therapeutics S L |
ANTI-CD36 ANTIBODIES AND THEIR USE FOR CANCER TREATMENT
|
EP4118118A1
(en)
|
2020-03-09 |
2023-01-18 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
US20230119066A1
(en)
|
2020-03-23 |
2023-04-20 |
Bristol-Myers Squibb Company |
Anti-ccr8 antibodies for treating cancer
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
AU2021256925A1
(en)
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
AU2021265801A1
(en)
|
2020-05-01 |
2022-11-17 |
Ngm Biopharmaceuticals, Inc. |
ILt-binding agents and methods of use thereof
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
US20230233474A1
(en)
|
2020-05-28 |
2023-07-27 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
JP2023532768A
(en)
|
2020-07-07 |
2023-07-31 |
バイオエヌテック エスエー |
RNA for treatment of HPV-positive cancer
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
US20230257365A1
(en)
|
2020-07-10 |
2023-08-17 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
TW202221031A
(en)
|
2020-07-30 |
2022-06-01 |
英商阿法克塔生命科學有限公司 |
Serum half-life extended pd-l1 inhibitory polypeptides
|
JP2023537412A
(en)
|
2020-08-13 |
2023-08-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
Methods of Redirecting IL-2 to Target Cells of Interest
|
MX2023002332A
(en)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Lag-3 antagonist therapy for hepatocellular carcinoma.
|
US20230303700A1
(en)
|
2020-08-31 |
2023-09-28 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
EP4232019A1
(en)
|
2020-10-23 |
2023-08-30 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
KR20230098279A
(en)
|
2020-10-28 |
2023-07-03 |
이케나 온콜로지, 인코포레이티드 |
Combinations of PDX inhibitors or doxorubicin with AHR inhibitors
|
US20240024320A1
(en)
|
2020-11-17 |
2024-01-25 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
US11753481B2
(en)
|
2020-12-18 |
2023-09-12 |
Lamkap Bio Beta Ltd |
Bispecific antibodies against CEACAM5 and CD47
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(en)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
Therapeutic rna for treating cancer
|
CN114656565B
(en)
*
|
2020-12-23 |
2024-04-23 |
广东菲鹏制药股份有限公司 |
Anti-PD-L1 antibody and application thereof
|
PE20240820A1
(en)
|
2020-12-28 |
2024-04-18 |
Bristol Myers Squibb Co |
COMPOSITIONS OF ANTIBODIES AND METHODS OF USE THEREOF
|
EP4267172A1
(en)
|
2020-12-28 |
2023-11-01 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
WO2022148736A1
(en)
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
MX2023007780A
(en)
|
2021-01-08 |
2023-07-10 |
Bristol Myers Squibb Co |
Combination therapy using an anti-fucosyl-gm1 antibody.
|
EP4282413A1
(en)
|
2021-01-21 |
2023-11-29 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
Composition and method for treating tumors
|
BR112023017296A2
(en)
|
2021-03-02 |
2023-11-14 |
Glaxosmithkline Ip Dev Ltd |
SUBSTITUTED PYRIDIINES AS DNMT1 INHIBITORS
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
TW202304506A
(en)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
BR112023019847A2
(en)
|
2021-03-29 |
2023-11-07 |
Juno Therapeutics Inc |
METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY
|
EP4314060A1
(en)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
CN113087801B
(en)
*
|
2021-04-07 |
2022-07-05 |
深圳市核子基因科技有限公司 |
Kit for jointly detecting lung cancer by using nucleic acid and antibody
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
US20230034659A1
(en)
*
|
2021-06-17 |
2023-02-02 |
Sparx Bioscience Limited |
Anti-pdl1 antibodies and uses thereof
|
EP4370552A1
(en)
|
2021-07-13 |
2024-05-22 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CA3230117A1
(en)
|
2021-09-02 |
2023-03-09 |
Mark Trautwein |
Anti-cecam6 antibodies with reduced side-effects
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
WO2023057534A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
TW202333802A
(en)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
Therapeutic rna for lung cancer
|
CA3234821A1
(en)
|
2021-10-28 |
2023-05-04 |
Suman Kumar VODNALA |
Methods for culturing immune cells
|
WO2023076989A1
(en)
|
2021-10-29 |
2023-05-04 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
AU2022375806A1
(en)
|
2021-10-29 |
2023-12-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023091951A1
(en)
*
|
2021-11-16 |
2023-05-25 |
The Regents Of The University Of California |
Methods to enhance therapeutic efficacy in melanoma via modulation of tumor cell surface pd-l1/l2
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023161453A1
(en)
|
2022-02-24 |
2023-08-31 |
Amazentis Sa |
Uses of urolithins
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023192946A1
(en)
*
|
2022-03-31 |
2023-10-05 |
Ventana Medical Systems, Inc. |
Methods and systems for predicting response to pd-1 axis directed therapeutics in colorectal tumors with deficient mismatch repair
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
WO2023196964A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine learning identification, classification, and quantification of tertiary lymphoid structures
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
WO2023230473A1
(en)
|
2022-05-24 |
2023-11-30 |
Bristol-Myers Squibb Company |
Antibodies that bind to human ccr8
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023242351A1
(en)
|
2022-06-16 |
2023-12-21 |
Lamkap Bio Beta Ag |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
WO2024015803A2
(en)
|
2022-07-11 |
2024-01-18 |
Autonomous Therapeutics, Inc. |
Encrypted rna and methods of its use
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|